Autoimmune Diseases  >>  ultra-rapid-acting recombinant human insulin (BIOD-123)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ultra-rapid-acting recombinant human insulin (BIOD-123) / Ipsen
NCT01686620: A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

Checkmark Preliminary data for diabetes
Sep 2013 - Sep 2013: Preliminary data for diabetes
Checkmark
Sep 2013 - Sep 2013: 
Checkmark
More
Completed
2
132
US
BIOD-123, Lispro (Humalog)
Biodel
Type 1 Diabetes Mellitus
06/13
06/13

Download Options